Just in: Biocon Secures China Approval for Tacrolimus Capsules, Boosting Global Reach

Biocon, a leading biopharmaceutical company, has received approval from Chinese authorities for its Tacrolimus capsules. This immunosuppressant drug is primarily used in organ transplant patients to prevent rejection, marking a significant milestone for Biocon's global expansion. The approval underscores Biocon’s commitment to delivering high-quality, affordable healthcare solutions across the globe. With this achievement, Biocon strengthens its foothold in the rapidly growing Chinese market, reinforcing its reputation as a global leader in pharmaceuticals.

NSE showed the stock closing at 373.25

Source: Biocon Press Release